The price to sequence a base [of the human genome] has fallen 100 million times. That’s the equivalent of you filling up your car with gas in 1998, waiting until 2011, and now you can drive to Jupiter and back twice.

Resnick uses an everyday cost comparison (gasoline) scaled to a fantastical distance (Jupiter) to make an abstract technological trend emotionally legible: the cost of DNA sequencing has collapsed at a rate that outpaces ordinary expectations about “exponential” progress. The point is not literal travel economics but the shock of magnitude—sequencing moved from a prohibitively expensive, specialized endeavor to something approaching routine infrastructure for research and, increasingly, medicine. The analogy also implies a shift in what becomes possible once costs fall: new applications, broader access, and a redefinition of the baseline for innovation in genomics.